Cytocares is a biotechnology startup that has been pioneering innovative medication development in the field of tumor immunity since its founding in 2015. The company's slogan, "Pioneering innovative medication development in the field of tumor immunity," reflects its commitment to pushing the boundaries of drug design for antibody novel medication creation and development in the realm of tumor immunity.
The latest milestone for Cytocares was the CNY100.00M Series A investment received on 17 May 2023. The investment was made by a consortium of notable investors, including Shenzhen Capital Group, 江苏金茂创业投资管理有限公司, Tailong Investment, Prosperico Ventures, and Bossage Genetics.
This significant investment not only validates the potential of Cytocares but also provides the necessary financial resources to further drive its innovative medication development in the field of tumor immunity. With strong investor backing, Cytocares is well-positioned to make a substantial impact in the biotechnology industry and bring novel medications to the forefront of tumor immunity treatment.
